). The total cumulative exposure to NRTIs was not P p .03 associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs studied. According to these results, monitoring of creatinine clearance, especially in patients with a low nadir CD4 + T lymphocyte count, could lead to modifications in antiretroviral therapy in order to diminish the risk of occurrence of lactic acidosis.
H I V / A I D S B R I E F R E P O R T

Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase
Inhibitors: A Case-Control Study 1000 patient-years [1] [2] [3] [4] . The occurrence of symptomatic lactic acidosis is a rare but life-threatening complication. The incidence of symptomatic lactic acidosis is approximately 1 case per 1000 patient-years and the associated mortality rate varies from 40 to 77% [5] [6] [7] [8] [9] [10] . With the exception of abacavir, all of the NRTIs used in treating HIV infection have been associated with lactic acidosis. Didanosine and stavudine have a higher capacity to inhibit the activity of DNA g-polymerase in vitro than do other NRTIs and have been associated in clinical studies with a higher risk for lactic acidosis in HIV-infected patients [4, 6, 11] . Some authors have suggested that female sex, obesity, and hepatic steatosis could be additional risk factors for lactic acidosis, but none of the previous reports have evaluated these factors, nor have they evaluated the cumulative time of exposure to the different NRTIs [10, 11] . Thus, we performed a case-control study of risk factors for lactic acidosis in HIVinfected patients being treated with NRTI therapy in southwestern France. Patients and methods. From May 1996 to June 2000, nine patients with lactic acidosis (defined as a plasma lactic acid level of 15 mM and a plasma pH of !7.38) that required intensive care were identified among HIV-infected patients receiving NRTI therapy in southwestern France. Patients were excluded from the study if they had lactic acidosis attributable to other causes: use of other drugs (silicylates, acetaminophen, biguanids, or isoniazid), exposure to toxic agents (cyanide, methanol, or ethylene glycol), acidocetosis, sepsis, neoplasm, or cirrhosis.
Given the small number of case patients, we increased the statistical power of our analysis by randomly selecting 14 times as many control patients as case patients from among a large cohort of patients who initiated a dual NRTI regimen in 1996 or after, were regularly followed up at our center, and did not develop lactic acidosis. Because of the absence of risk factors for lactic acidosis that are clearly described in the literature, we choose not to match the control patients with case patients. The end point of the study was 30 June 2000.
Data were collected by medical practitioners who reviewed the patients' charts using a standardized data collection instrument. For each patient, data were collected relating to the time period between the initiation of antiretroviral therapy and either the date of diagnosis of lactic acidosis (for case patients) or the last date of follow-up (for control patients). All of these patients are included in the Aquitaine cohort of HIV-infected patients in southwestern France, and written informed consent to participate has been obtained [12] .
Clinical and laboratory data were retrospectively reviewed, NOTE. NRTI, nucleoside reverse transcriptase inhibitor; AZT, zidovudine; ddI, dideoxyinosine; ddC, zalcitibine; d4T, stavudine; 3TC, lamivudine; RF, renal failure (creatinine clearance !70 mL/min); HBV, hepatitis B virus infection; ENT, ear, nose, and throat infection; HCV, hepatitis C infection; HT, hypertension.
and included the following: age at the last date of follow-up; sex; known duration of HIV infection; hepatitis B and C serological status; cirrhosis status; creatinine clearance (as calculated by Cockroft/Gault equation [13] , determined at least 1 month before the diagnosis of lactic acidosis, for case patients, or quarterly during follow-up, for control patients; CD4 + T lymphocyte count at the nadir and at the last date of followup; treatment history; and cumulative duration of exposure to antiretroviral drugs.
Frequency of hypothesized risk factors was tabulated for case patients and control patients. Differences between case patients and control patients were tested using t tests, for continuous variables, and the x 2 test, for categorical variables. Relative risk estimates were calculated using the empirical OR. The cutoffs for the different variables were determined on the basis of the median value for the whole group of patients. The exception was creatinine clearance, for which we used 2 different thresholds: 60 mL/min, which defined renal failure, and 70 mL/min, which was determined on the basis of the values noted in the 9 case patients.
Results. The main characteristics of the 9 case patients are summarized in table 1. The median age of the 4 men and 5 women was 36 years (range, 33-63 years). Risk factors for HIV transmission were injection drug use ( ), being a man who n p 4 has sex with men ( ), heterosexual sex ( ), and unn p 2 n p 1 known (
). The median time since diagnosis of HIV inn p 2 fection was 9 years (range, 0.5-13 years). Median CD4 + T lymphocyte count at the time of lactic acidosis diagnosis was 197 cells/mm 3 (range, 31-707 cells/mm 3 ). The causes of hospital admission were abdominal pain ( ), dyspnea ( ), asn p 6 n p 6 thenia ( ), jaundice ( ), and vomiting ( ). Hen p 5 n p 4 n p 2 patomegaly was present in 6 patients. Lactic acidosis was found in all case patients: median pH, 7.28; bicarbonate level, 12 mM; anion gap, 27 mEq/L; plasma lactic acid level, 13 mM. Cytolysis ( patients), cholestasis ( ), hepatic failure ( ), n p 8 n p 6 n p 4 rhabdomyolysis ( ), and pancreatitis ( ) were also n p 4 n p 2 present. No patient had a history of obesity, and the median body mass index (measured in 8 patients) was 20.1 (range, 14-28) at the time of diagnosis of lactic acidosis. Lactate measurements were not available during follow up. The median time since beginning antiretroviral therapy was 4 years (range, 4 months-8 years). At the time of lactic acidosis diagnosis 1 patient was being treated with an NRTI monotherapy (lamivudine) and 8 patients were being treated with an NRTI dual therapy (table 1) . At the time of lactic acidosis diagnosis, the mean duration of the last NRTI regimen was 12 weeks (range,
), and ear, nose, and throat infections n p 1 ( ), all of which started 1-15 days before lactic acidosis n p 2 diagnosis.
We identified as significant risk factors for lactic acidosis (table 2) a creatinine clearance below 70 mL/min and a low nadir CD4 + T lymphocyte count. Although higher percentages of women, hepatitis B or C coinfected patients, and patients with poor immunological responses at the end of follow-up were noted in the group of patients with lactic acidosis, the differences were not statistically significant in relation (P 1 .05) to the control group. Age and total cumulative exposure to NRTIs were not associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs we studied. Four (44%) of the 9 patients had received at least 1 course of stavudine and didanosine, compared with 12 (29%) of 41 control subjects (
). There was no statistically significant differ-P p .44 ence between the percentage of patients who received at least 1 course of stavudine or didanosine during follow-up and developed lactic acidosis and the percentage of those in the control group.
Discussion. This study has demonstrated 2 previously unreported risk factors for NRTI-associated lactic acidosis: first, a decreased creatinine clearance to !70 mL/min, and, second, a low nadir CD4 + T lymphocyte count before the inception of a regimen containing NRTIs. We are aware that our study has limitations because of the small number of cases. This may be explained by the low incidence of lactic acidosis (calculated in our cohort at 1.1 cases per 1000 patient-years among NRTItreated patients) and a strict selection of our cases. It is unlikely that biases introduced by the study design can explain the patterns seen. Particularly, total drug exposure was not different between the case patients and the control patients, even though we did not match for this variable.
We have shown that low creatinine clearance is a major risk factor for lactic acidosis. It could be hypothesized that renal failure diminishes the clearance of NRTIs and favors drug accumulation and also that renal dysfunction does not allow compensation for the hyperlactatemia frequently seen in patients receiving NRTIs. It is noteworthy that data on renal function is never mentioned in the case reports and retrospective studies recently published on lactic acidosis. We think that the evaluation of renal function, particularly in cases of acute infection or concomitant prescription of nephrotoxic drugs, could allow some cases of lactic acidosis to be prevented. Nevertheless, the management of NRTI therapy in patients with renal failure is not clearly defined. It is usually recommended that the NRTI dosage should be decreased, but this recommendation should be assessed by measurements of the intracytoplasmic phosphorylated nucleosid level and/or changes in the mitochondrial DNA, which are not routinely performed [14] . At the present time it seems cautious to recommend that, in case of a significant decrease in creatinine clearance, NRTI therapy should be discontinued, to limit the risk of occurrence of lactic acidosis.
The second risk factor for lactic acidosis-namely, a low nadir CD4 + T lymphocyte count before the inception of NRTI therapy-was already suggested by Coghlan et al. [6] . In their retrospective study, 10 of 12 patients had histories of nadir CD4 + T lymphocyte counts of !200 cells/mm 3 . Such patients should be carefully monitored with respect to their clinical symptoms and biological data, especially renal function and plasma lactic acid level.
Recently, Moyle et al. [11] showed that females were overrepresented among 9 patients with severe hyperlactatemia or lactic acidosis, and, in a review of 40 case patients, Megarbane et al. [5] noted a male to female ratio of 1.18:1, which represents a high rate of hyperlactatemia or lactic acidosis among females when one takes into account the higher prevalence of HIV infection in males. Although not statistically significant, the tendency noted in our study is not discordant with these data.
Coinfection with hepatitis B or C viruses has been poorly studied in HIV-infected patients with hyperlactatemia or lactic acidosis, although the impact of hepatitis B or C viruses on the toxicity of most drugs has been described. Our results (66% of cases were coinfected) are similar to those described by Falco et al. [7] (8 HCV coinfected subjects among 12 patients). Further studies should take into account this factor.
The present study provides no evidence that the duration of a regimen containing NRTIs increases the risk of lactic acidosis. For example, 3 of our patients were treated for !10 months, and, in the retrospective study by Coghlan et al. [6] , the median total duration of lifetime antiretroviral exposure was only 21 months (range, 6-70 months). Recently, several studies have implicated therapy with stavudine and/or didanosine as a risk factor for hyperlactatemia or lactic acidosis [4, 6, 11] . These results are concordant with those for in vitro models that have shown that human mitochondrial DNA g-polymerase has an increased power of affinity for stavudine and didanosine, but our study and others show that fatal lactic acidosis may also occur with regimens that do not include these 2 drugs [15] [16] [17] [18] [19] . Therefore, the occurrence of lactic acidosis could depend on other individual factors, as we have demonstrated.
In conclusion, we have found, in this case-control study, 2 main risk factors for lactic acidosis: low creatinine clearance, and low nadir CD4 + T lymphocyte count before inception of NRTI therapy. According to the findings of previous studies, it seems that female sex might be added to this list. Other potential risk factors, such as viral hepatitis coinfection, steatosis and obesity, acute infections, receipt of other prescribed drugs, and the genetic characteristics of patients, have to be investigated in large prospective studies.
